October 29, 2023
3 min watch
Save
VIDEO: Interim results promising for RGX-314 in diabetic retinopathy
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
SEATTLE — In this Healio Video Perspective from the ASRS meeting, Dilsher Dhoot, MD, discusses the interim results of the phase 2 ALTITUDE trial investigating three doses of RGX-314 gene therapy in diabetic retinopathy.
“If we look at dose levels one and two, we saw ‘any improvement’ in [Diabetic Retinopathy Severity Scale] of 54% in both doses combined compared to 20% improvement in the sham group,” he said.
Dhoot also discussed 6-month safety data.
Published by:
Sources/Disclosures
Collapse
Source:
Dhoot D. Suprachoroidal delivery of RGX-314 gene therapy for diabetic retinopathy: The phase II ALTITUDE study. Presented at: American Society of Retina Specialists annual meeting; July 28-Aug. 1, 2023; Seattle.
Disclosures:
Dhoot reports being a consultant for and an investor in Regenxbio.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.